Literature DB >> 30498135

Mixed Reviews for A2AR Inhibitor in NSCLC.

.   

Abstract

Findings of a phase I/II trial of the adenosine 2A receptor blocker NIR178 combined with the PD-1 inhibitor spartalizumab in advanced non-small cell lung cancer suggest that the drugs are safe. Two of 25 patients showed complete or partial responses, and 13 had stable disease. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 30498135     DOI： 10.1158/2159-8290.CD-NB2018-157

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  2 in total

1.  Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.

Authors:  Veronika Voronova; Kirill Peskov; Yuri Kosinsky; Gabriel Helmlinger; Lulu Chu; Alexandra Borodovsky; Richard Woessner; Kris Sachsenmeier; Wenlin Shao; Rakesh Kumar; Gayle Pouliot; Melinda Merchant; Holly Kimko; Ganesh Mugundu
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

2.  Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.

Authors:  Yu Bai; Xin Zhang; Jie Zheng; Ziyi Liu; Zhenfan Yang; Xiaolin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.